Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Retained Earnings (2016 - 2025)

Palisade Bio (PALI) has disclosed Retained Earnings for 16 consecutive years, with -$143.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings changed N/A to -$143.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$143.8 million, a N/A change, with the full-year FY2024 number at -$135.9 million, down 11.88% from a year prior.
  • Retained Earnings was -$143.8 million for Q3 2025 at Palisade Bio, down from -$141.0 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$2776.0 in Q1 2021 to a low of -$143.8 million in Q3 2025.
  • A 5-year average of -$113.6 million and a median of -$121.5 million in 2023 define the central range for Retained Earnings.
  • Biggest YoY gain for Retained Earnings was 61.16% in 2021; the steepest drop was 2401179.48% in 2021.
  • Palisade Bio's Retained Earnings stood at -$95.7 million in 2021, then dropped by 14.08% to -$109.2 million in 2022, then fell by 11.28% to -$121.5 million in 2023, then dropped by 11.88% to -$135.9 million in 2024, then dropped by 5.8% to -$143.8 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Retained Earnings are -$143.8 million (Q3 2025), -$141.0 million (Q2 2025), and -$138.2 million (Q1 2025).